Atalanta Sosnoff Capital LLC increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 471,142 shares of the pharmaceutical company’s stock after acquiring an additional 81,541 shares during the quarter. Vertex Pharmaceuticals comprises about 2.3% of Atalanta Sosnoff Capital LLC’s investment portfolio, making the stock its 16th biggest holding. Atalanta Sosnoff Capital LLC owned about 0.19% of Vertex Pharmaceuticals worth $70,605,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of the stock. Keybank National Association OH increased its stake in Vertex Pharmaceuticals by 5.3% during the 2nd quarter. Keybank National Association OH now owns 4,587 shares of the pharmaceutical company’s stock valued at $591,000 after purchasing an additional 232 shares in the last quarter. Commerce Bank bought a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at about $206,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at about $465,000. Schroder Investment Management Group increased its stake in Vertex Pharmaceuticals by 8.0% during the 2nd quarter. Schroder Investment Management Group now owns 33,398 shares of the pharmaceutical company’s stock valued at $4,250,000 after purchasing an additional 2,478 shares in the last quarter. Finally, Private Advisor Group LLC increased its stake in Vertex Pharmaceuticals by 2.4% during the 2nd quarter. Private Advisor Group LLC now owns 5,457 shares of the pharmaceutical company’s stock valued at $702,000 after purchasing an additional 129 shares in the last quarter. Institutional investors own 93.19% of the company’s stock.
A number of analysts have recently issued reports on VRTX shares. BMO Capital Markets reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. Robert W. Baird reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, January 9th. Cowen reissued a “buy” rating and issued a $200.00 price objective on shares of Vertex Pharmaceuticals in a report on Monday, December 11th. Finally, Bank of America raised shares of Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $180.00 price objective on the stock in a report on Friday, January 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating, twenty-five have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $175.89.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down $2.22 on Tuesday, reaching $155.71. 1,789,451 shares of the company traded hands, compared to its average volume of 1,574,755. Vertex Pharmaceuticals Incorporated has a 12 month low of $79.78 and a 12 month high of $167.85. The company has a market capitalization of $39,380.00, a PE ratio of 199.63, a PEG ratio of 1.86 and a beta of 1.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company had revenue of $578.20 million for the quarter, compared to analysts’ expectations of $522.07 million. During the same quarter in the previous year, the business posted $0.16 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 39.7% on a year-over-year basis. analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.76 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by BBNS and is the property of of BBNS. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/atalanta-sosnoff-capital-llc-acquires-81541-shares-of-vertex-pharmaceuticals-incorporated-vrtx/1821248.html.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.